No data available that match "Anti-Obesity Agents"



*  Patent US7601691 - Anti-obesity agents - Google Patents

Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or ... Moreover, the anti-obesity activity of the conjugated anti-obesity peptide derivatives of the present invention is considerably ... is a diagram showing a comparison between the anti-obesity activity of PYY3-36 and the anti-obesity activity a compound ... A new anti-obesity agent that has an enhanced activity and which would permit to avoid the above-mentioned drawbacks would ...

*  Pramlintide Combined With Model Predictive Control Algorithm - Full Text View - ClinicalTrials.gov

Hypoglycemic Agents. Physiological Effects of Drugs. Appetite Depressants. Anti-Obesity Agents. Amylin Receptor Agonists. ... If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past ...

*  New Treatment for Alcohol and Nicotine Dependence - Full Text View - ClinicalTrials.gov

Anti-Infective Agents, Local. Anti-Infective Agents. Central Nervous System Depressants. Physiological Effects of Drugs. ... Autonomic Agents. Peripheral Nervous System Agents. Nicotinic Agonists. Cholinergic Agonists. Cholinergic Agents. ... Neurotransmitter Agents. Molecular Mechanisms of Pharmacological Action. Anticonvulsants. Neuroprotective Agents. Protective ... Hence, due to this unique anti-withdrawal effect of topiramate, we propose to adopt the same methodology for treating alcohol- ...

*  Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine - Full Text View -...

... nonsteroidal anti-inflammatory drugs (NSAIDs) daily, opioids, agents for insomnia (e.g., Ambien, diphenhydramine-containing OTC ... Neuroprotective Agents. Protective Agents. Physiological Effects of Drugs. Anti-Obesity Agents. To Top ... Onset of migraine occurred after age 50 years, or overuse of analgesics or migraine specific agents for the acute treatment of ...

*  Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS - Full Text View -...

Antidepressive Agents. Psychotropic Drugs. Appetite Depressants. Anti-Obesity Agents. ClinicalTrials.gov processed this record ... There are only a few studies on the effect of anti-obesity drug administration in obese and overweight women with PCOS. To the ... Studies on the effect of sibutramine, an anti-obesity drug, on hormonal and metabolic features of women with polycystic ovary ... Obesity, particularly of the abdominal type, is presented in approximately half of the women with PCOS, although several ...

*  A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy - Full Text View -...

Neuroprotective Agents. Protective Agents. Physiological Effects of Drugs. Anti-Obesity Agents. To Top ... Topiramate is an anti-epileptic drug that is approved for the treatment of epilepsy in adults and children 2 years of age and ... Topiramate is an anti-epileptic drug that is approved for epilepsy either alone (i.e., monotherapy), or in combination with ... Any number of factors could affect the dosage needs for an anti-epileptic medication, however, various lines of evidence ...

*  Topiramate Treatment for Patients With Epilepsy and Learning Disability : A Prospective Observational Study - Full Text View -...

Neuroprotective Agents. Protective Agents. Physiological Effects of Drugs. Anti-Obesity Agents. To Top ...

*  Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence - Full Text View -...

Neuroprotective Agents. Protective Agents. Anti-Obesity Agents. ClinicalTrials.gov processed this record on September 18, 2017 ... Anti-Infective Agents, Local. Anti-Infective Agents. Central Nervous System Depressants. Physiological Effects of Drugs. ...

*  Comparison Between Dexchlorpheniramine and Dexchlorpheniramine/Pseudoephedrine/Guaifenesin in Respiratory Infections - Full...

Autonomic Agents. Peripheral Nervous System Agents. Physiological Effects of Drugs. Anti-Asthmatic Agents. Respiratory System ... Vasoconstrictor Agents. Central Nervous System Stimulants. Sympathomimetics. Adrenergic Agents. Neurotransmitter Agents. ... Also, allergic rhinitis makes the mucosa more reactive to infectious agents and potentiates mucus production. ...

*  Topiramate in Adolescents With Severe Obesity - Full Text View - ClinicalTrials.gov

Neuroprotective Agents. Protective Agents. Physiological Effects of Drugs. Anti-Obesity Agents. To Top ... Obesity. Weight Loss. Obesity, Morbid. Overnutrition. Nutrition Disorders. Overweight. Body Weight. Signs and Symptoms. Body ... The prevalence of severe pediatric obesity is on the rise and youth with this condition are at elevated risk for developing ... The prevalence of severe pediatric obesity is on the rise and youth with this condition are at elevated risk for developing ...

*  Topiramate for the Treatment of Methamphetamine Dependence - 1 - Full Text View - ClinicalTrials.gov

Anti-Obesity Agents. Central Nervous System Stimulants. Sympathomimetics. Autonomic Agents. Peripheral Nervous System Agents. ... Dopamine Agents. Neurotransmitter Agents. Molecular Mechanisms of Pharmacological Action. Adrenergic Agents. Adrenergic Uptake ... Neuroprotective Agents. Protective Agents. Physiological Effects of Drugs. ...

*  A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects - Full Text...

Antidepressive Agents. Psychotropic Drugs. Appetite Depressants. Anti-Obesity Agents. To Top. *For Patients and Families ...

*  A Toolbox Approach to Obesity Treatment in Primary Care - Full Text View - ClinicalTrials.gov

Neuroprotective Agents. Protective Agents. Physiological Effects of Drugs. Anti-Obesity Agents. Central Nervous System ... Autonomic Agents. Peripheral Nervous System Agents. Adrenergic Agents. Neurotransmitter Agents. Molecular Mechanisms of ... Documentation of Obesity [ Time Frame: 1 year study period ]. To assess:. *Presence of ICD-9 code for obesity in the DHHA ... Usual care for obesity at DH includes brief weight loss advice provided by PCPs or prescribing of weight loss medication, for ...

*  A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects -...

Obesity. Antiobesity agents. Antiobesity drugs. Overweight drug therapy. Obese drug therapy. Weight loss drug effects. ... Sensory System Agents. Peripheral Nervous System Agents. Antidepressive Agents, Second-Generation. Antidepressive Agents. ... Have BMI ≥30 and ≤45kg/m² for subjects with uncomplicated obesity, and BMI of ≥27 and ≤45kg/m² for subjects with obesity and ... Dopamine Agents. Neurotransmitter Agents. Cytochrome P-450 CYP2D6 Inhibitors. Cytochrome P-450 Enzyme Inhibitors. Enzyme ...

*  Gymnema Sylvestre | GreenMedInfo | Substance | Natural Medicine

Diseases : Obesity. Pharmacological Actions : Anti-Inflammatory Agents, Interleukin-6 Downregulation, Tumor Necrosis Factor ( ... Lactobacillus plantarum LP625 alone or supplemented with herbs seems to protect against diet induced obesity.Feb 29, 2016. ... Powdered Gymnema sylvestre, Citrulus colocynthis, and Artemisia absinthium possess good anti-diabetic features.Aug 31, 2015. ...

*  Oleuropein | GreenMedInfo | Substance | Natural Medicine

Additional Keywords : Anti-Obesity Agents. [+] Oleuropein improves glucose tolerance and lipid profile in rats with ... Anti-Inflammatory Agents, Anticholesteremic Agents, Antihypertensive Agents, Antioxidants, Hypoglycemic Agents ... Pharmacological Actions : Anti-Inflammatory Agents, Antihypertensive Agents, Antioxidants. Additional Keywords : Plant Extracts ... Additional Keywords : Anti-Inflammatory Agents, Antioxidants, Heart Failure, Myocardial Infarction, Oleuropein, oxidative ...

*  The relationship between BMI and the prescription of anti-obesity medication according to social factors: a population cross...

General practice Anti-obesity agents Socioeconomic factors Weight loss Obesity Multi-level modelling ... are more likely to be prescribed anti-obesity medication.. What is already known on this topic. Anti-obesity medication has ... relate uptake of anti-obesity medications to need and; 2) quantify the amount of variation in prescribing of anti-obesity ... Prescribing of anti-obesity medication reflected obesity prevalence across urban/rural areas and deprivation. There was an ...

*  Study of the Pathogenesis of Rett Syndrome - Full Text View - ClinicalTrials.gov

Neuroprotective Agents. Protective Agents. Anti-Obesity Agents. Antitussive Agents. Respiratory System Agents. Excitatory Amino ... Cholinergic Agents. Neurotransmitter Agents. Physiological Effects of Drugs. Nootropic Agents. Anticonvulsants. ...

*  Xenical Disease Interactions - Drugs.com

Peripherally acting antiobesity agents. Related Drugs. Obesity Alli, phentermine, amphetamine, Contrave, liraglutide, Saxenda, ... and the dosages of these agents adjusted accordingly. Patients should be apprised of the risk of hypoglycemia and be alert to ...

*  Prevalence of weight-loss strategies and use of substances for weight-loss among adults: a population study

Keywords : Weight Loss; Anti-obesity Agents; Phytotherapy; Cross-Sectional Studies. · abstract in Portuguese · text in English ...

*  Molecules | Free Full-Text | Response Surface Modeling and Optimization of Accelerated Solvent Extraction of Four Lignans from...

Screening of Anti-Obesity Agent from Herbal Mixtures. Previous Article in Journal. Effect of the Molecular Mass of Tremella ...

*  ALPHA-LIPOIC ACID: Uses, Side Effects, Interactions and Warnings - WebMD

Doggrell, S. A. Alpha-lipoic acid, an anti-obesity agent? Expert.Opin.Investig.Drugs 2004;13(12):1641-1643. View abstract. ... Amelioration of lipid abnormalities by a-lipoic acid through antioxidative and anti-inflammatory effects. Obesity (Silver ... Jameel, N. M., Shekhar, M. A., and Vishwanath, B. S. Alpha-lipoic acid: an inhibitor of secretory phospholipase A2 with anti- ... Takasaki, J., Ono, K., Yoshiike, Y., Hirohata, M., Ikeda, T., Morinaga, A., Takashima, A., and Yamada, M. Vitamin A has anti- ...

*  D Piomelli

Oleylethanolamide derivatives as anti-obesity agents. Daniele Piomelli; Fiscal Year: 2005. *Role of oleoylethanolamide in the ... The results suggest that OEA regulates lipid metabolism and that this effect may contribute to its anti-obesity properties... ... neurotransmitter agents*oleic acids*cannabinoids*amidohydrolases*neurons*drug receptors*bornanes*supraoptic nucleus*laboratory ... that OEA stimulates fat utilization through activation of PPAR-alpha and that this effect may contribute to its anti-obesity ...

*  Effects of Su-Huang Antitussive Capsule on Cough Variant Asthma - Full Text View - ClinicalTrials.gov

Anti-Obesity Agents. Sympathomimetics. Autonomic Agents. Peripheral Nervous System Agents. Nasal Decongestants. Vasoconstrictor ... Respiratory System Agents. Expectorants. Adrenergic alpha-Agonists. Adrenergic Agonists. Adrenergic Agents. Neurotransmitter ... Antitussive Agents. Guaifenesin. Phenylpropanolamine. Chlorpheniramine, phenylpropanolamine drug combination. ... Agents. Molecular Mechanisms of Pharmacological Action. Physiological Effects of Drugs. Appetite Depressants. ...

*  PPT - Micronutrients Vitamins and Minerals PowerPoint Presentation - ID:4023338

... anti T.B), mineral oil, orlistat (xenical antiobesity), sucralfate (ulsanic gastric ulcer), and the fat substitute, olestra. ... I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described. ... is there a better solution???. if there was a magic pill obesity ... Many of the anti-oxidant properties of Vitamin E have been ... and non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, ibuprofen, and others. ...

No data available that match "Anti-Obesity Agents"



(1/472) Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update.

Beta 3-adrenoceptor (beta 3-AR) agonists were found to have remarkable anti-obesity and anti-diabetic effects in rodents shortly after their discovery in the early 1980s. Despite these promising qualities, several pharmaceutical problems and theoretical concerns have slowed the development of these products as therapeutic agents in humans during the last 15 years. To date, the pharmaceutical industry has not been successful in developing a beta 3-AR agonist for use in the treatment of human obesity and type 2 diabetes. Pharmaceutical problems in this area concern important differences between rodent and human beta 3-AR and the difficulty in finding a compound with sufficient bioavailability that is a highly selective and full agonist at the human receptor. Some of these problems seem to have been solved with the cloning of the human beta 3-AR, which has made it possible to develop novel compounds directly and specifically against the human receptor. However, several theoretical concerns still remain. These include the major question as to whether the number of biologically active beta 3-ARs in adult humans is sufficient to produce relevant metabolic effects and, if so, whether their long-term stimulation is safe and free of unwarranted side effects. In addition, the mechanisms of action of beta 3-AR agonists remain poorly understood. Recent studies using CL 316,243, a highly selective beta 3-adrenergic compound, have provided new insights into the potential mechanisms of action of these drugs in rodents as well as the first evidence that treatment with a highly selective beta 3-AR agonist exerts relevant metabolic effects in humans. It appears that chronic beta 3-adrenergic stimulation in white adipose tissue increases the expression of newly discovered mitochondrial uncoupling proteins (UCP 2 and 3) and a "reawakening" of dormant brown adipocytes. In addition, beta 3-ARs may be present in skeletal muscle where ectopic expression of UCP-1 has been reported. If these findings are confirmed, tissues other than brown fat may play an important role in mediating beta 3-adrenergic effects on thermogenesis and substrate oxidation. In humans, treatment with CL 316,243 for 8 weeks, in spite of limited bioavailability, induced marked plasma concentration-dependent increases in insulin sensitivity, lipolysis, and fat oxidation in lean volunteers, without causing beta 1-, or beta 2-mediated side effects. These results clearly indicate that favourable metabolic effects can be achieved by selective beta 3-AR stimulation in humans. The compounds of the next generation currently emerging from preclinical development are full agonists at the human beta 3-AR. These agents have demonstrated promising results in non-human primates. It will be interesting to see whether their efficacy in clinical trials is superior to that achieved with previous (rodent) beta 3-AR agonists and, if so, whether their effects will eventually translate into weight loss and improved metabolic control that could facilitate their use as effective drugs for the treatment of obesity and Type 2 diabetes in humans.  (+info)

(2/472) Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.

BACKGROUND: Long-term maintenance of weight loss remains a therapeutic challenge in obesity treatment. OBJECTIVE: This multicenter, double-blind, placebo-controlled study was designed to test the hypothesis that orlistat, a gastrointestinal lipase inhibitor, is significantly more effective than a placebo in preventing weight regain. DESIGN: Obese subjects who lost > or = 8% of their initial body weight during a 6-mo lead-in of a prescribed hypoenergetic diet (4180-kJ/d deficit) with no adjunctive pharmacotherapy were randomly assigned to receive placebo, 30 mg orlistat, 60 mg orlistat, or 120 mg orlistat 3 times daily for 1 y in combination with a maintenance diet to help prevent weight regain. Of 1313 recruited subjects [body mass index (in kg/m2): 28-43], 729 subjects lost > or =8% of their initial body weight during the 6-mo weight-loss lead-in period and were enrolled in the double-blind phase. RESULTS: After 1 y, subjects treated with 120 mg orlistat 3 times daily regained less weight than did placebo-treated subjects (32.8 +/- 4.5% compared with 58.7 +/- 5.8% regain of lost weight; P < 0.001). Moreover, more subjects in the 120-mg orlistat group than in the placebo group regained < or = 25% of lost weight (47.5% of subjects compared with 29.9%). In addition, orlistat treatment (120 mg 3 times daily) was associated with significantly greater reductions in total and LDL-cholesterol concentrations than was placebo (P < 0.001). CONCLUSION: The use of orlistat during periods of attempted weight maintenance minimizes weight readjustment and facilitates long-term improvement in obesity-related disease risk factors.  (+info)

(3/472) The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones.

The antihypertensive agent moxonidine, an imidazoline Ii-receptor agonist, also induces hypophagia and lowers body weight in the obese spontaneously hypertensive rat, but the central mediation of this action and the neuronal pathways that moxonidine may interact with are not known. We studied whether moxonidine has anti-obesity effects in the genetically-obese and insulin-resistant fa/fa Zucker rat, and whether these are mediated through inhibition of the hypothalamic neuropeptide Y (NPY) neurones. Lean and obese Zucker rats were given moxonidine (3 mg kg(-1) day(-1)) or saline by gavage for 21 days. Moxonidine decreased food intake throughout by 20% in obese rats (P<0.001) and by 8% in lean rats (P<0.001), and reduced weight gain that final body weight was 15% lower in obese (P<0.001) and 7% lower in lean (P<0.01) rats than their untreated controls. Plasma insulin and leptin levels were decreased in moxonidine-treated obese rats (P<0.01 and P<0.05), but unchanged in treated lean rats. Uncoupling protein-1 gene expression in brown adipose tissue was stimulated by 40-50% (P< or =0.05) in both obese and lean animals given moxonidine. Obese animals given moxonidine showed a 37% reduction in hypothalamic NPY mRNA levels (P = 0.01), together with significantly increased NPY concentrations in the paraventricular nucleus (P<0.05), but no changes in the arcuate nucleus or other nuclei; this is consistent with reduced NPY synthesis in the arcuate nucleus and blocked release of NPY in the paraventricular nucleus. In lean animals, moxonidine did not affect NPY levels or NPY mRNA. The hypophagic, thermogenic and anti-obesity effects of moxonidine in obese Zucker rats may be partly due to inhibition of the NPY neurones, whose inappropriate overactivity may underlie obesity in this model.  (+info)

(4/472) Review article: malnutrition and maltreatment--a comment on orlistat for the treatment of obesity.

The prevalence of obesity has doubled in the last 10 years and is now reaching epidemic proportions. There is a significant comorbidity and financial cost associated with this disorder. Orlistat is an intestinal lipase inhibitor that is approved for the treatment of obesity. Recent randomized, double-blind, placebo-controlled trials have demonstrated the benefit of orlistat used in conjunction with a hypocaloric (low-fat) diet in facilitating weight reduction and the long-term maintenance of this weight loss. Patients treated with orlistat lost a greater amount of initial body weight compared to those who received placebo. After 24 months of treatment, weight loss of more than 5% was maintained in a greater number of those treated with orlistat. This was associated with significant reductions in cardiovascular risk factors (cholesterol, LDL cholesterol, LDL:HDL cholesterol ratio). The main adverse events are related to fat malabsorption, with potential losses of fat-soluble vitamins and other compounds. Orlistat as a treatment for obesity, when prescribed within present guidelines, can aid modest weight loss in about one-third of patients. More importantly, it can assist in the maintenance of weight loss with major medical benefits for these patients.  (+info)

(5/472) Orlistat. No hurry....

Treatments for obesity are disappointing. None has yet shown an effect on morbidity and mortality. Nondrug treatments are poorly assessed. Stable long-term weight loss necessitates long-term management. Orlistat (Xenical, Hoffman-La Roche), a gastrointestinal lipase inhibitor, is indicated, in combination with a low-calorie diet, for management of obesity. The assessment file is bulky and methodologically sound, at least in terms of the weight loss end point. During medium-term trials (12 to 24 months), orlistat administered at a dose of 120 mg three times daily and combined with dietary intervention had a moderate positive effect on body weight (-3.5 kg on average). No longer-term trials have been done. It is unknown whether this drug affects morbidity and mortality linked to obesity. In clinical trials, patients treated with orlistat had an increased frequency of breast cancer. This potential risk is currently being assessed in a specific trial. Gastrointestinal adverse effects are frequent. Treatment is costly.  (+info)

(6/472) Drug therapy for obesity.

Obesity is a common health problem in the United States, and effective treatment is challenging. Obesity is associated with an increased mortality rate and risk factors such as hypertension, hyperlipidemia and diabetes mellitus. Numerous treatments are available for obesity. Behavioral therapy, surgery and pharmacologic treatment have been used with varying degrees of success. Older anorectic agents have significant side effects and limited benefit, and some have even been withdrawn from the U.S. market because of a possible association with cardiovascular complications. The safety of newer agents must be extensively evaluated before widespread use is recommended. Therefore, behavioral therapy, including regular exercise and the development of healthy eating habits, continues to be the best treatment for long-term weight loss.  (+info)

(7/472) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi)

BACKGROUND: Chinese-herb nephropathy is a progressive form of renal fibrosis that develops in some patients who take weight-reducing pills containing Chinese herbs. Because of a manufacturing error, one of the herbs in these pills (Stephania tetrandra) was inadvertently replaced by Aristolochia fangchi, which is nephrotoxic and carcinogenic. METHODS: The diagnosis of a neoplastic lesion in the native urinary tract of a renal-transplant recipient who had Chinese-herb nephropathy prompted us to propose regular cystoscopic examinations and the prophylactic removal of the native kidneys and ureters in all our patients with end-stage Chinese-herb nephropathy who were being treated with either transplantation or dialysis. Surgical specimens were examined histologically and analyzed for the presence of DNA adducts formed by aristolochic acid. All prescriptions written for Chinese-herb weight-reducing compounds during the period of exposure (1990 to 1992) in these patients were obtained, and the cumulative doses were calculated. RESULTS: Among 39 patients who agreed to undergo prophylactic surgery, there were 18 cases of urothelial carcinoma (prevalence, 46 percent; 95 percent confidence interval, 29 to 62 percent): 17 cases of carcinoma of the ureter, renal pelvis, or both and 1 papillary bladder tumor. Nineteen of the remaining patients had mild-to-moderate urothelial dysplasia, and two had normal urothelium. All tissue samples analyzed contained aristolochic acid-related DNA adducts. The cumulative dose of aristolochia was a significant risk factor for urothelial carcinoma, with total doses of more than 200 g associated with a higher risk of urothelial carcinoma. CONCLUSIONS: The prevalence of urothelial carcinoma among patients with end-stage Chinese-herb nephropathy (caused by aristolochia species) is a high.  (+info)

(8/472) Detection of impaired intestinal absorption of long-chain fatty acids: validation studies of a novel test in a rat model of fat malabsorption.

BACKGROUND: Classic fat balance studies detect fat malabsorption but do not discriminate between the potential causes of malabsorption, such as impaired intestinal lipolysis or reduced uptake of fatty acids. OBJECTIVE: We aimed to validate a novel test for the specific, sensitive detection of impaired intestinal uptake of long-chain unesterified fatty acids in an appropriate rat model of fat malabsorption. DESIGN: The absorption and appearance in plasma of [(13)C]palmitic acid were determined in control rats and in rats with fat malabsorption due either to chronic bile deficiency (permanent bile diversion) or to oral administration of the lipase inhibitor orlistat (200 mg/kg diet). [(13)C]Palmitic acid results were compared with the percentage absorption of ingested dietary fat determined by fat balance. RESULTS: Between 1 and 6 h after intraduodenal administration, plasma [(13)C]palmitate concentrations in control rats were 4-10-fold higher than in bile-deficient rats (P < 0.05) but were not significantly different between orlistat-supplemented rats and their controls. In control and bile-deficient rats, plasma [(13)C]palmitate concentrations allowed complete discrimination between normal (>92%) and reduced (<92%) fat absorption, whereas the percentage absorption of [(13)C]palmitate over 48 h appeared to be highly correlated with the percentage absorption of ingested dietary fat (r = 0.89, P < 0.001). CONCLUSIONS: The [(13)C]palmitic acid absorption test detects impaired intestinal absorption of long-chain fatty acids selectively and sensitively in a rat model of fat malabsorption due to bile deficiency. Our data strongly support the use of the [(13)C]palmitic acid absorption test for the diagnosis of clinical fat malabsorption syndromes.  (+info)



Sibutramine

  • Studies on the effect of sibutramine, an anti-obesity drug, on hormonal and metabolic features of women with polycystic ovary syndrome (PCOS) are lacking. (clinicaltrials.gov)
  • To the authors' best knowledge, the effect of sibutramine, a serotonin and noradrenaline reuptake inhibitor (SNRI) approved as antiobesity drug, has been studied in only one study with obese women with PCOS. (clinicaltrials.gov)
  • In Northern Ireland, during 2009/2010 orlistat accounted for approximately 80% of prescriptions for anti-obesity medication increasing to 99% following the withdrawal of sibutramine. (biomedcentral.com)

obese

  • Several studies have demonstrated that obesity in women with PCOS enhances the clinical and metabolic abnormalities of the syndrome, since obese women with PCOS have more profound insulin resistance or type 2 DM,dyslipidemia and cardiovascular disease's risk, and greater level of androgens due to low SHBG levels. (clinicaltrials.gov)
  • There are only a few studies on the effect of anti-obesity drug administration in obese and overweight women with PCOS. (clinicaltrials.gov)
  • Although not FDA approved for the treatment of obesity, studies in obese adults have demonstrated weight reduction of approximately 5% with 6-12 months of therapy. (clinicaltrials.gov)
  • While 25.0% of people are obese, only 1.3% (2.1% of females, 0.6% of males) received anti-obesity medication. (biomedcentral.com)

prevalence

  • The prevalence of severe pediatric obesity is on the rise and youth with this condition are at elevated risk for developing chronic diseases such as cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). (clinicaltrials.gov)
  • Prescribing of anti-obesity medication reflected obesity prevalence across urban/rural areas and deprivation. (biomedcentral.com)
  • There is evidence of relative under-prescribing in males compared to females despite a similar prevalence of obesity. (biomedcentral.com)
  • While the prevalence (and presumably the health consequences) of obesity worsens with age, younger females are more likely to be prescribed anti-obesity medication. (biomedcentral.com)

medication

  • Any number of factors could affect the dosage needs for an anti-epileptic medication, however, various lines of evidence suggest that characteristics of the patient's epilepsy itself could be important determinants. (clinicaltrials.gov)
  • One option is the use of anti-obesity medication the prescription of which has increased dramatically in recent years. (biomedcentral.com)
  • Despite this, little is known about the individual and GP practice factors that influence the prescription of anti-obesity medication. (biomedcentral.com)
  • Multi-level logistic regression analysis was used to investigate factors associated with the prescription of anti-obesity medication in Northern Ireland using a population primary care prescribing database (~1.5 million people aged 16+ years) during 2009/10. (biomedcentral.com)
  • There was an unexplained two-fold difference, between the 25th and 75th percentile, in the GP practice prescription of anti-obesity medication. (biomedcentral.com)
  • Educational material to improve the understanding of the role of anti-obesity medication, for patients and practitioners, is recommended. (biomedcentral.com)
  • Orlistat (brand names Xenical/Alli) was first introduced in the UK and Europe in 1998 and is currently the main treatment option for those prescribed anti-obesity medication. (biomedcentral.com)
  • Therefore, patients with type 2 diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce significant weight loss as a secondary effect) for hypoglycemia and reduced need for oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly. (drugs.com)

Topiramate

  • Topiramate is an anti- epileptic drug that is approved for the treatment of epilepsy in adults and children 2 years of age and above. (clinicaltrials.gov)
  • Topiramate is an anti-epileptic drug that is approved for epilepsy either alone (i.e., monotherapy), or in combination with other anti-epileptic medications, in adults and children 2 years of age and above. (clinicaltrials.gov)
  • Therefore, the goal of this pilot study is to evaluate the safety and efficacy of 24 weeks of topiramate therapy with a 4-week run-in of meal replacement therapy in adolescents with severe obesity. (clinicaltrials.gov)

medications

  • In recent years, pharmacological treatment for obesity has been increasing against a backdrop of decreasing choice of available anti-obesity medications. (biomedcentral.com)

treatment

  • Most primary care settings do not provide much obesity treatment, though, as primary care providers (PCPs) are not well trained and because reimbursement for treatments is not consistent. (clinicaltrials.gov)
  • The remainder of the registry's patients can still receive obesity treatment but will not be reimbursed. (clinicaltrials.gov)
  • Impact: If the study is successful, we plan to take the results to the leaders at Denver Health to see if they will make obesity treatment more broadly available for all patients there. (clinicaltrials.gov)
  • The purpose of this study is to determine whether 2 doses of the combination of naltrexone SR and bupropion SR are safe and effective in the treatment of obesity. (clinicaltrials.gov)

Patients

  • Patients who have been identified by their physicians as candidates for initial anti-epileptic monotherapy will be enrolled. (clinicaltrials.gov)
  • Lifestyle modification therapy alone is ineffective for most adolescents with severe obesity and few patients qualify for bariatric surgery. (clinicaltrials.gov)

present

  • Although lean women present PCOS, obesity is one of the main manifestations of the syndrome. (clinicaltrials.gov)

Actions

  • Oleuropein and hydroxytyrosol exhibit anti-diabetic and antioxidant actions. (greenmedinfo.com)

effective

  • A range of treatments have shown to be effective for treating obesity. (clinicaltrials.gov)

patient

  • Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof. (google.ca)

features

  • Powdered Gymnema sylvestre, Citrulus colocynthis, and Artemisia absinthium possess good anti-diabetic features. (greenmedinfo.com)

effects

  • Oleuropein exhibits anti-ischemic, antioxidative, and hypolipidemic effects in anesthetized rabbits. (greenmedinfo.com)